{"id":"piprozolin","rwe":[],"tags":[{"label":"piprozolin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A05AX01","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"probilin","offLabel":[],"synonyms":["piprozoline","probilin","piprozolin"],"timeline":[],"approvals":[],"brandName":"Probilin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"piprozolin","explanation":"Think of it like a key that unlocks a specific process in the body. By fitting into a particular spot, it can either turn the process on or off, or even change how it works. This can have different effects depending on the process and where it's happening in the body.","oneSentence":"Piprozolin is believed to work by modulating certain biological pathways.","technicalDetail":"Piprozolin's exact mechanism of action is unknown, but it is thought to interact with specific receptors or enzymes to produce its effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2196","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIPROZOLIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:25:21.017698","biosimilars":[],"competitors":[{"drugName":"maralixibat hydrochloride","drugSlug":"maralixibat-hydrochloride","fdaApproval":"2021-09-29","relationship":"same-class"},{"drugName":"odevixibat","drugSlug":"odevixibat","fdaApproval":"2021-07-20","patentExpiry":"Nov 8, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"piprozolin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"maralixibat-hydrochloride","brandName":"maralixibat hydrochloride","genericName":"maralixibat hydrochloride","approvalYear":"2021","relationship":"same-class"},{"drugId":"odevixibat","brandName":"odevixibat","genericName":"odevixibat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"007558","UNII":"7786W0VV8M","CHEBI":"CHEBI:135262","INN_ID":"2509","RXNORM":"33761","UMLSCUI":"C0071123","ChEMBL_ID":"CHEMBL2105231","KEGG_DRUG":"D05489","DRUGBANK_ID":"DB13202","PUBCHEM_CID":"5911905","MESH_SUPPLEMENTAL_RECORD_UI":"C003155"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A05AX01","allCodes":["A05AX01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piprozolin, also known as Probilin, is a small molecule drug in the piprozolin class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain biological pathways. Piprozolin's commercial status and approved indications are unclear, and it is not known whether it is FDA-approved or off-patent. Further research is needed to fully understand its effects and potential uses. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}